Stable Therapeutic Formulations
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 60/754,948, filed Dec 28, 2005. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,573,717 | Stable Therapeutic Formulations In force · High confidence | Alza Corporation | In force | High confidence | ||
| US 8,632,801 | Stable Therapeutic Formulations In force · Medium confidence | Alza Corporation | In force | Medium confidence | ||
| US 11,179,324 | Stable Therapeutic Formulations In force · High confidence | Alza Corporation | In force | High confidence | ||
| Application 17/502,701 | Stable Therapeutic Formulations Abandoned Abandoned Feb 6, 2026 | Alza Corporation | Abandoned | Abandoned Feb 6, 2026 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Alza Corporation.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.